Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Terminated NCT02251249

Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.

Conditions: Impairment of Gastric Emptying, Acute Phase of Myocardial Infarction

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 23
Sponsor: University Hospital, Bordeaux

Location: CHU de Bordeaux - Hôpital du Haut Lévèque Pessac

Summary

Oral antiplatelet therapy is a key treatment of the STEMI (ST elevation myocardial infarction). Delayed action isn't suitable and has to be elucidated. If a delayed gastric emptying time is observed during STEMI, limiting the use of morphine and encourage the use of prokinetic agents can be a first answer to optimize coronary angioplasty environment. Investigators propose a study to assess the gastric emptying times at the acute phase of myocardial infarction using a validated paracetamol absorption test. The STEMI group will be compared to in one hand, itself with measures performed 72 hours±12h after the event onset; and on the other hand, to a stable patient group referred for angioplasty for angina or non-ST-segment elevation myocardial infarction (NSTEMI). For STEMI group and stable patient group, the delay of apparition of Prasugrel or Ticagrelor efficacy will be determined by VerifyNow® test and correlated to gastric emptying times.

Eligibility Criteria

Inclusion Criteria: * Patient over 18 years weighing between 65 and 85 Kg * Referred for STEMI within 6 hours from beginning of chest pain or stable coronary artery disease requiring a loading dose of Prasugrel or Ticagrelor according to the international recommendations. * No previous treatment with Clopidogrel, Prasugrel or Ticagrelor. * Patient fasting for at least 6 hours. * Affiliate or receiving a social security system. * Written informed consent. Exclusion Criteria: * Allergy or contraindication to paracetamol, Prasugrel or Ticagrelor * Paracetamol ingestion in the previous 48 hours * Patient treated with drugs supposed to alter gastric emptying times (calcium antagonists, Alimentary tract treatments, opioid analgesics, tricyclic antidepressants, antibiotics). * Conditions or pathologies supposed to alter gastric emptying times (Thyroid dysfunction, chronic renal failure, Parkinson's disease, scleroderma, amyloidosis, any gastrointestinal disease, any not cured malignancy, and any advanced psychiatric or neurological disease). * Presence of vomiting * Cardiogenic shock, ventricular arrhythmia or resuscitated cardiac arrest * Hepatic insufficiency * Severe respiratory disease * Pregnant or breastfeeding women

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02251249). StuddyBuddy aggregates publicly available trial information.